🏢 官网IRTHRMCodex · 实盘不做把握 6/10
北京时间·🕒 发布 04:00:00时区推断·⟳ 抓取 04:00:27回填·⚡ 决策 07-21 04:02:15·98.7 天前
Gentherm 医疗业务 ThermAffyx 患者安全系统获得 FDA 510(k) 许可
FDA 数据库确认 ThermAffyx 于 2026-07-08 获 510(k) substantial equivalence 决定，公司 2026-07-20 盘后发布新闻稿。
📄 原文THRM↗ 原文
Gentherm Medical Receives FDA Clearance for ThermAffyx™ Patient Safety System
Skip to main navigation Gentherm Medical Receives FDA Clearance for ThermAffyx™ Patient Safety System Jul 20, 2026 PDF…
不做 Gentherm（THRM.US）
FDA 许可方向偏利好但未披露订单、售价或采购承诺，Medical segment 仅约 5000 万美元、占公司收入约 3.3%，短期财务增量不足以支撑盘后开仓追多，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA 记录显示 ThermAffyx Patient Safety System 的 510(k) 决定日期为 2026-07-08，结论为 substantial equivalence。
- 公司盘后公告获得 FDA 许可，称 8月开始医疗机构产品试用、2026Q3 开始产生收入。市场反应:THRM.US 事件前收 35.57 美元，当日 -1.03%。
关键理由
- FDA 数据库确认 ThermAffyx 于 2026-07-08 获 510(k) substantial equivalence 决定，公司 2026-07-20 盘后发布新闻稿。
- 该产品可用于机器人辅助手术中的主动保温和固定，但公司只称 2026Q3 开始产生收入，未披露订单、定价、装机量或医院采购承诺。
- Gentherm 2025 年总收入约 15.0 亿美元，Medical segment 约 4978 万美元，约占总收入 3.3%；即便新品进入试用，短期收入增量仍难以支撑 10.9 亿美元市值的盘后追多。
主要风险
- 若后续披露大型医院系统订单、单价或耗材经常性收入模型，事件重大性可能上修。
- 公司近期 5日/20日股价分别约 -1.5%/-1.0%，没有明显抢跑，但这也说明市场尚未给该 FDA 许可定价为强催化。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部库未命中与 ThermAffyx 收入量级、医院订单或销售预测相关的有效证据。
检索:Gentherm ThermAffyx FDA clearance patient safety system revenue medical segment - 做多前查反向 · 来源 web · 日期 2026-02-19 · 影响 weakens
公司 2025 年 Medical segment 收入约 4978 万美元，同比基本持平，说明该业务基数小且缺少高增长确认。
检索:Gentherm medical segment decline revenue 2025 patient temperature management 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- kb_search · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 3,165 字
Skip to main navigation
Gentherm Medical Receives FDA Clearance for ThermAffyx™ Patient Safety System
Jul 20, 2026
PDF Version
The company’s new patented integrated warming and securement device seamlessly addresses unique challenges in robotic surgery
NOVI, Mich. , July 20, 2026 (GLOBE NEWSWIRE) -- Gentherm , a global market leader of innovative thermal management and pneumatic comfort technologies, announced today it received FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System . This Class II medical device combines active patient warming, securement and pressure reduction in a single platform designed for the more than 3 million robotic-assisted surgical procedures performed annually worldwide. Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to commence in Q3 2026.
Historically, surgical teams have pieced together separate solutions to address warming and securement issues. ThermAffyx simplifies that process by combining two critical patient safety functions into a single system that fits naturally into existing surgical workflows.
Traditional underbody securement pads help prevent patient movement but do not provide active warming. This is especially problematic in robotic procedures and surgeries that require the patient to be tilted in Trendelenburg position. Studies have found that only 17% to 21% of a patient's body surface area may be available for forced-air warming during these procedures, and more than one-quarter of robotic surgery patients are hypothermic in recovery, despite warming interventions.
The ThermAffyx Patient Safety System was developed to address this gap by integrating active underbody warming directly into an anti-slip securement pad. The radiolucent heating element is powered by Gentherm's proprietary Carbotex® carbon-fiber heating technology. This is more than a new warming device. It's a purpose-built patient safety platform designed around the realities of modern robotic surgery.
The FDA clearance follows Gentherm's 510(k) submission announced earlier this year and represents a significant expansion of the company's patient temperature management portfolio.
About Gentherm
Gentherm (NASDAQ: THRM) is a global market leader of innovative thermal management and pneumatic comfort technologies. Automotive products include Climate Control Seats (CCS®), Climate Control Interiors (CCI™), Lumbar and Massage Comfort Solutions, and Valve Systems. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 14,000 employees in facilities across 13 countries. In 2025, the company recorded annual sales of approximately $1.5 billion and secured $2.2 billion in automotive new business awards. For more information, go to www.gentherm.com.
Investor Contact
Gregory Blanchette
investors@gentherm.com
248.308.1702
Media Contacts
Haley Baur
media@gentherm.com
248.289.9711
Search Investors
Gentherm Medical Receives FDA Clearance for ThermAffyx™ Patient Safety System
Jul 20, 2026
PDF Version
The company’s new patented integrated warming and securement device seamlessly addresses unique challenges in robotic surgery
NOVI, Mich. , July 20, 2026 (GLOBE NEWSWIRE) -- Gentherm , a global market leader of innovative thermal management and pneumatic comfort technologies, announced today it received FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System . This Class II medical device combines active patient warming, securement and pressure reduction in a single platform designed for the more than 3 million robotic-assisted surgical procedures performed annually worldwide. Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to commence in Q3 2026.
Historically, surgical teams have pieced together separate solutions to address warming and securement issues. ThermAffyx simplifies that process by combining two critical patient safety functions into a single system that fits naturally into existing surgical workflows.
Traditional underbody securement pads help prevent patient movement but do not provide active warming. This is especially problematic in robotic procedures and surgeries that require the patient to be tilted in Trendelenburg position. Studies have found that only 17% to 21% of a patient's body surface area may be available for forced-air warming during these procedures, and more than one-quarter of robotic surgery patients are hypothermic in recovery, despite warming interventions.
The ThermAffyx Patient Safety System was developed to address this gap by integrating active underbody warming directly into an anti-slip securement pad. The radiolucent heating element is powered by Gentherm's proprietary Carbotex® carbon-fiber heating technology. This is more than a new warming device. It's a purpose-built patient safety platform designed around the realities of modern robotic surgery.
The FDA clearance follows Gentherm's 510(k) submission announced earlier this year and represents a significant expansion of the company's patient temperature management portfolio.
About Gentherm
Gentherm (NASDAQ: THRM) is a global market leader of innovative thermal management and pneumatic comfort technologies. Automotive products include Climate Control Seats (CCS®), Climate Control Interiors (CCI™), Lumbar and Massage Comfort Solutions, and Valve Systems. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 14,000 employees in facilities across 13 countries. In 2025, the company recorded annual sales of approximately $1.5 billion and secured $2.2 billion in automotive new business awards. For more information, go to www.gentherm.com.
Investor Contact
Gregory Blanchette
investors@gentherm.com
248.308.1702
Media Contacts
Haley Baur
media@gentherm.com
248.289.9711
Search Investors
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。